425 related articles for article (PubMed ID: 8259554)
21. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
22. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
23. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
24. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
27. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
28. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
29. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
31. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
32. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
33. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.
Bellart J; Gilabert R; Fontcuberta J; Carreras E; Miralles RM; Cabero L
Am J Perinatol; 1998 Feb; 15(2):81-5. PubMed ID: 9514130
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy.
Ballegeer V; Mombaerts P; Declerck PJ; Spitz B; Van Assche FA; Collen D
Thromb Haemost; 1987 Dec; 58(4):1030-2. PubMed ID: 3445223
[TBL] [Abstract][Full Text] [Related]
35. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
36. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
37. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
38. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
39. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
40. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
